Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 04:30 ET | Source: Oculis Holding AG

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to...
October 28, 2025 07:00 ET | Source: GHO Capital

GHO Capital announces final close of Fund IV with over €2.5bn of capital to continue investing in its strategy of driving better, faster and more accessible healthcare

Fund IV brings total Assets Under Management (AUM) to c. €9 billion, making GHO the largest healthcare specialist private equity firm headquartered in Europe GHO has diversified its investor base...
October 28, 2025 04:00 ET | Source: GHO Capital

GHO Capital announces final close of Fund IV with over €2.5bn of capital to continue investing in its strategy of driving better, faster and more accessible healthcare

Fund IV brings total Assets Under Management (AUM) to c. €9 billion, making GHO the largest healthcare specialist private equity firm headquartered in Europe GHO has diversified its investor base...
October 06, 2025 07:05 ET | Source: 4Bio Capital

4BIO Capital founded Trogenix secures £70 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers

Trogenix was founded by 4BIO as a spinout from the University of Edinburgh alongside Professor Steve Pollard and Dr Ken Macnamara in 2023Trogenix's breakthrough Odysseus® platform targets cancer cells...
October 06, 2025 02:05 ET | Source: 4Bio Capital

4BIO Capital founded Trogenix secures £70 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers

Trogenix was founded by 4BIO as a spinout from the University of Edinburgh alongside Professor Steve Pollard and Dr Ken Macnamara in 2023Trogenix's breakthrough Odysseus® platform targets cancer cells...
October 06, 2025 02:00 ET | Source: Trogenix

Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers

Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancersFinancing...
September 24, 2025 09:00 ET | Source: Bastion

Bastion Surpasses $40 Million in Funding Amid Explosive Growth in the Stablecoin Market

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Bastion, a regulated stablecoin infrastructure provider, today announced it has exceeded $40 million in total funding to date following a $14.6 million...
September 23, 2025 08:00 ET | Source: Zero Hash Holdings LLC

Interactive Brokers leads zerohash capital raise, as Morgan Stanley, Apollo and SoFi also make significant Onchain-Infrastructure Investment - zerohash Reaches Unicorn Status and is now valued at $1 Billion

NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The leading crypto and stablecoin infrastructure platform–zerohash–today announced a $104 million Series D-2 raise. Led by Interactive Brokers, one of...
September 02, 2025 07:00 ET | Source: Charm Therapeutics

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...
September 02, 2025 02:00 ET | Source: Charm Therapeutics

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...